Pharmaceutical or cosmetic composition promoting hair growth

A wheat gluten extract-based composition containing sphingolipids, digalactosyldiacylglycerol, and phospholipids effectively addresses hair loss by enhancing the anagen phase, resulting in increased hair length and density over 12 weeks of use.

FR3148362A1Pending Publication Date: 2024-11-08SOC DEXPLOITATION DE PROD POUR LES IND CHEM SEPPIC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
FR2023004535
Authority / Receiving Office
FR · FR
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-05
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing treatments for hair loss conditions such as alopecia and telogen effluvium are inadequate in promoting hair growth effectively, particularly due to disruptions in the hair growth cycle caused by stress, pollution, hormonal imbalance, or drug treatment, leading to weakened hair structures and non-localized hair loss.

Method used

A composition comprising sphingolipids, digalactosyldiacylglycerol, and phospholipids derived from wheat gluten extracts, administered orally, to promote hair growth by enhancing the anagen phase and increasing the density and length of hair.

Benefits of technology

The composition significantly increases hair length, regrowth, and density by improving the proportion of hair in the anagen phase, demonstrating a noticeable aesthetic improvement in hair growth within 12 weeks of daily oral administration.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Composition (C) comprising, by weight: 20% to 80% by weight of at least one sphingolipid (a1), 10% to 50% by weight of digalactosyldiacylglycerol (a2), and 1% to 30% by weight of at least one phospholipid (a3), for use in a therapeutic treatment method intended to promote hair growth. Pharmaceutical composition (Cp) and food supplement (Ca) comprising said composition (C). Non-therapeutic use of said food supplement (Ca) and non-therapeutic method of preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Title of the invention: Pharmaceutical or cosmetic composition promoting hair growth

[0001] The invention relates to the field of cosmetics and pharmacy. It relates to treatment to promote hair growth.

[0002] The hair fiber consists of a visible shaft, a hair bulb, located under the surface of the scalp, and a dermal papilla located at the base of the bulb. The shaft is made up of three concentric layers: the medulla, the cortex and the cuticle. The medulla is the central part, while the cortex is the intermediate layer and constitutes the body of the hair. The cortex is composed of long chains of keratin which give the hair its elasticity, flexibility and strength. The hair fiber is protected by the cuticle, formed by keratin scales sealed to each other by an intercellular cement rich in lipids and in particular ceramides. These lipid substances ensure the barrier function of the hair by giving it a certain impermeability.

[0003] At its base, the shaft is surrounded by two sheaths: the outer epithelial sheath, which has a composition similar to that of the epidermis, and the inner epithelial sheath, rich in glycoproteins, constituting the nourishing base of the developing hair. The hair bulb is composed of keratinocytes whose active division is responsible for the formation of the hair shaft, as well as the inner and outer epithelial sheaths. The dermal papilla is a highly vascularized area and constitutes the site of the cell multiplication necessary for hair growth. It is composed of fibroblasts and ensures nutrition, irrigation, oxygenation and the elimination of cellular waste from the hair.

[0004] Hair grows according to a growth cycle composed of three successive phases: the anagen phase (growth phase), the catagen phase (regression phase) and the telogen phase (resting phase).

[0005] The anagen phase is a growth phase, lasting on average 2 to 4 years in men and up to 6 years in women. This phase is characterized by rapid proliferation and differentiation of keratinocytes to form the hair and epithelial sheaths. The intense metabolic activity at the bulb level leads to the formation of keratin, a protein essential to the composition of hair. Under normal conditions, approximately 85% of the hair is in the anagen phase.

[0006] The catagen phase is a regression phase, lasting a short time of two to three weeks, constituting the transition phase between the growth phase and the resting phase. This phase is characterized by the involution of the hair follicle by a programmed death phenomenon. Cell differentiation decreases until it stops. The volume of the bulb decreases, the latter rises towards the surface of the epidermis until it causes the physical connection with the dermal papilla to break. This phase affects approximately 1% of the hair.

[0007] The telogen phase is a resting phase preceding hair loss, lasting an average of two to three months. This phase is characterized by an absence of cell proliferation. The dead hair remains attached to the hair follicle, and falls out when it is pushed out by a new hair, for which a new anagen phase begins. This phase concerns approximately 10 to 15% of the hair.

[0008] Under the influence of various factors, this hair cycle can be altered. In particular, stress, fatigue, pollution, hormonal imbalance or drug treatment can lead to abundant and non-localized hair loss, called telogen effluvium. In this case, the proportion of hair in the telogen phase increases, which can be greater than 20%. This is called telogen effluvium. This disruption generally lasts between two and four months and is accompanied by a weakening of the hair structure.

[0009] The proportion of hair in the anagen and telogen phases can be assessed by performing a phototrichogram, a standardized method measuring the fundamental parameters linked to hair growth.

[0010] The phototrichogram is carried out on a fixed area of ​​the scalp with a diameter of 1.8 cm (fronto-temporal region or vertex). The hair is shaved there before a first macrophotograph allowing the total hair to be counted; a second macrophotograph taken 48 hours later then allows the anagen hair that has grown to be differentiated from telogen hair that has not grown.

[0011] As part of their research aimed at developing the use of natural compounds in therapy and cosmetics, the inventors have demonstrated that the use of a composition derived from wheat gluten extracts, administered orally, is capable of promoting hair growth (or growth), particularly in people suffering from alopecia or telogen effluvium.

[0012] According to a first aspect, the invention thus relates to a composition (C) comprising for 100% by mass: - From 20% by mass to 80% by mass of at least one sphingolipid (al), - From 10% by mass to 50% by mass of digalactosyldiacylglycerol (a2), and - From 1% by mass to 30% by mass of at least one phospholipid (a3),

[0013] for its use in a therapeutic treatment method intended to promote hair growth.

[0014] For the purposes of the present invention, the term "sphingolipids" means complex lipids resulting from the amidation of a fatty acid on sphingosine. Sphingosine is an amido-diol having an ethylenic double bond; called 2-amino-octadec-4-ene-1,3-diol and of formula (I): OH (I)

[0015] For the purposes of the present invention, the term "phospholipid" means a lipid comprising a phosphoric acid group in the form of a monoester or diester, and more particularly phosphoethanolamines, phosphatidylinositol, lyso-phosphatidylethanolamines, phosphatidic acids, phosphatidylcholine and lysophosphatidylcholines.

[0016] According to a first particular aspect, the composition (C) as defined above comprises, for 100% by mass, from 20% by mass to 60% by mass, of at least one sphingolipid (al).

[0017] According to a second particular aspect, the composition (C) as defined above comprises, for 100% by mass, from 19% by mass to 50% by mass, of digalactosyldia-cylglycerol (a2).

[0018] According to a third particular aspect, the composition (C) as defined above comprises, for 100% by mass, from 1% by mass to 10% by mass, of at least one phospholipid (a3).

[0019] The invention more particularly relates to a composition (C) comprising for 100% by mass: - From 20% by mass to 60% by mass, of at least one sphingolipid (al), - From 19% by mass to 50% by mass, of digalactosyldiacylglycerol (a2), and - From 1% by mass to 10% by mass, of at least one phospholipid (a3),

[0020] for its use in a therapeutic treatment method intended to promote hair growth.

[0021] According to another particular aspect of the invention, the composition (C) as defined above is characterized in that the sum of the mass contents of said at least one sphingolipid (a1), of said digalactosyldiacylglycerol (a2) and of said at least one phospholipid (a3), is equal to 100% by mass.

[0022] According to another particular aspect of the invention, the composition (C) as defined above is in oily form or in powder form.

[0023] According to another particular aspect of the invention, said composition (C) is a cereal extract, in particular a wheat gluten extract.

[0024] Said composition (C) as defined above, is prepared by methods known to those skilled in the art and more particularly that described in the application international patent application published under number WO 99 / 65459, on pages 8 to 11. It is more particularly prepared according to a process comprising the following successive steps:

[0025] - At least one step a) of providing wheat gluten flour,

[0026] - At least one step b) of adding wheat gluten flour to ethanol (97% minimum) under mechanical stirring for a period of at least two hours and at a temperature of 60°C,

[0027] - At least one step c) of spinning followed by a sub-step of decantation of the mixture obtained in step b) so as to recover a homogeneous liquid phase,

[0028] - At least one step d) of vacuum distillation of the liquid obtained during step c), at a temperature less than or equal to 35°C to remove the ethanol so as to obtain a concentrated composition,

[0029] - At least one step e) of adding the product obtained at the end of step d) to ethanol, with mechanical stirring and at a temperature of 4°C, so as to precipitate the medium and recover the liquid part,

[0030] - At least one step f) of distillation of the liquid obtained at the end of step e) for remove the ethanol and obtain an oily composition,

[0031] - At least one step g) of adding composition (C) to acetone so as to obtain a precipitate,

[0032] - At least one step h) of filtration of the medium obtained at the end of step g) allowing the recovery of a powdery solid,

[0033] - drying the solid cake obtained at the end of step g) to obtain a com position in powder form.

[0034] The present invention also relates to an edible pharmaceutical composition (Cp) comprising for 100% by mass:

[0035] - more than 0% by mass to 30% by mass of said composition (C) as defined above- above and

[0036] - from 70% by mass to less than 100% by mass of at least one technological additive pharmaceutically acceptable edible.

[0037] Preferably, said edible pharmaceutical composition (Cp) comprises for 100% by mass:

[0038] - from 10% by mass to 30% by mass of said composition (C) as defined above- above and

[0039] - from 70% by mass to 90% by mass of at least one edible technological additive pharmaceutically acceptable.

[0040] By "technological additive" is meant any chemical substance or any chemical composition whose technical function is to allow and / or facilitate the mixing of the different constituents of said edible composition, to facilitate and / or to optimize the physical properties of said edible composition, such as facilitating and / or optimizing its flow, its stability, and its incorporation into a subsequent pharmaceutical and / or nutritional formulation, and which are likely to comply with the conditions required by the regulations in force for the placing on the market of a pharmaceutical formulation and / or a nutritional formulation.

[0041] By pharmaceutically acceptable technological additive is meant a technological additive whose use meets the requirements of the pharmaceutical regulations in force in a country concerned.

[0042] According to a particular aspect of the invention, said pharmaceutically acceptable edible technological additive is chosen from a diluting agent, a flow agent, a binding agent or a disintegrating agent.

[0043] As diluting agent, there are for example lactose, sucrose, saccharose, glucose, maltodextrin, mannitol, sorbitol, xylitol, isomalt, calcium hydrogen phosphate, microcrystalline cellulose, starches such as corn, wheat or potato starches, dicalcium phosphate, sodium, calcium or magnesium carbonates, monoglycerides and / or diglycerides of fatty acids containing from 8 to 24 carbon atoms.

[0044] As flow agents, there are for example magnesium stearate, talc, sodium stearyl fumarate, hydrogenated vegetable oils, anhydrous colloidal silica, sodium benzoate or silica dioxide.

[0045] As binding agents, there are for example starches in the form of starch, pregelatinized starches, hydroxypropylmethyl cellulose (HPMC), methylcellulose, sucrose syrups or acacia gum.

[0046] Examples of disintegrating agents include starches, sodium starch glycolate, alginic acid, sodium alginate, croscarmellose sodium, crospovidone, or polyvinylpyrrolidone.

[0047] According to a particular aspect of the invention, said edible pharmaceutical composition (Cp) as defined above, further comprises at least one active ingredient chosen from bioactive lipids, water-soluble or water-dispersible trace element salts, water-soluble or fat-soluble vitamins, prebiotics, probiotics, proteins and / or milk protein concentrates, plant or animal enzymes, amino acids, peptides, sugars, flavor enhancers and flavoring agents.

[0048] As bioactive lipids possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example phytosterols, such as those extracted from vegetable oils, and more particularly extracts of sea buckthorn oil, corn oil or soybean oil; phytosterol complexes isolated from vegetable oils, such as cholestatin composed of campesterol, stigmasterol and brassicasterol; phytostanols; carotenoids, which belong to the family of terpenoids extracted from algae, green plants, fungi, bacteria; polyunsaturated fatty acids of the omega-3 group, such as alpha-linoleic acid, eicosapentaenoic acid, docosahexaenoic acid; polyunsaturated fatty acids of the omega-6 group, such as linoleic acid, g-linoleic acid, eicosadienoic acid, dihomo-y-linoleic acid, arachidonic acid, docosadienoic acid, docosatetraenoic acid, docosapentaenoic acid.

[0049] As salts of water-soluble or water-dispersible trace elements possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example ferrous carbonate, ferrous chloride tetrahydrate, ferric chloride hexahydrate, ferrous citrate hexahydrate, ferrous fumarate, ferrous lactate tetrahydrate, ferrous sulfate monohydrate, ferrous sulfate heptahydrate, ferrous chelate of amino acids hydrates, iron chelate of glycine; calcium iodate hexahydrate, anhydrous calcium iodate; sodium iodide, potassium iodide; cobalt acetate tetrahydrate, basic cobalt carbonate monohydrate, cobalt carbonate hexahydrate, cobalt sulfate heptahydrate, cobalt sulfate monohydrate, cobalt nitrate hexahydrate;cupric acetate monohydrate, basic copper carbonate monohydrate, cupric chloride dihydrate, copper methionate, cupric sulfate pentahydrate, cuprous chelate of amino acids hydrates, cuprous chelate of glycine hydrate, copper chelate of hydroxy analogue of methionine; manganous carbonate, manganous chloride tetrahydrate, manganese acid phosphate trihydrate, manganous sulfate tetrahydrate, manganese sulfate monohydrate, manganese chelate of amino acids hydrate, manganese chelate of glycine hydrate, manganese chelate of hydroxy analogue of methionine; ammonium molybdate, sodium molybdate, sodium selenite, sodium selenate; the organic form of selenium produced by Saccharomyces cerevisiae, selenomethionine (inactivated selenium yeast), and seleno methionine produced by Saccharomyces cerevisiae (inactivated selenium yeast). ;

[0050] As water-soluble or fat-soluble vitamins possibly present in said edible pharmaceutical composition (Cp) as defined above, there is for example vitamin A, more particularly in its form of retinol, retinyl acetate, retinyl palmitate or beta-carotene; vitamin D2, more particularly in its form of ergocalciferol, or 25-hydroxy calciferol; vitamin D3, more particularly in its form of cholecalciferol; vitamin K, more particularly in its form of phylloquinone (phytomenadione) or Menaquinone; vitamin B1, more particularly in its form of thiamine hydrochloride, thiamine mononitrate, thiamine chloride monophosphate, or thiamine chloride thiamine pyrophosphate, vitamin B2, more particularly in its form of riboflavin, riboflavin 5'-phosphate sodium, vitamin B6, more particularly in its form of pyridoxine hydrochloride, pyridoxine 5'-phosphate, or pyridoxal 5'-phosphate, vitamin B12, more particularly in its form of cyanocobalamin, hydroxocobalamin, 5'-deoxyadenosylcobalamin, or methylcobalamin, vitamin C, more particularly in its form of L-ascorbic acid, sodium L-ascorbate, calcium L-ascorbate, potassium L-ascorbate, calcium salts of palmityl-6-L-ascorbic acid, sodium ascorbyl monophosphate, pantothenic acid, more particularly in its form of calcium D-pantothenate, D- sodium pantothenate, Dexpanthenol, or Pantethine, vitamin PP, more particularly in its form of nicotinic acid, niacin, ni-cotinamide, or inositol hexanicotinate (inositol hexaniacinate), vitamin B9,more particularly in its folic acid form, folates, more particularly in their pteroylmonoglutamic acid form, calcium L-methylfolate, (6S)-5-methyltetrahydrofolic acid in the form of glucosamine salt, vitamin H2, B7 or BW, more particularly in its biotin form, choline, more particularly in its choline chloride form, choline dihydrogen citrate, choline bitartrate, inositol, carnitine, more particularly in its L-carnitine form, L-carnitine-L-tartrate, taurine.

[0051] As prebiotics possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example inulin, trans-galacto-oligosaccharides, fructans and manno-oligosaccharides.

[0052] As probiotics possibly present in said edible pharmaceutical composition (Cp) as defined above, there are different strains of Sac-charomyces cerevisiae, Bacillus cereus var toyoi, Bacillus subtilis alone or in combination with Bacillus licheniformis, or strains of Enteroccocus faecium. These strains of microorganisms are generally associated with a solid support, for example calcium carbonate, dextrose or sorbitol.

[0053] As proteins and / or protein concentrates possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example milk proteins derived from milk, such as colostrum in the form of lyophilized or atomized powder or whey in the form of powder, purified fractions or enriched with IgG, lactoferrin, lactoperoxidase.

[0054] As plant or animal enzymes possibly present in the edible pharmaceutical composition (Cp) as defined above, there are for example promutase, superoxide dismutase (SOD), 3-phytase, 6-phytase, endo-1,4-betaglucanases, endo-1,4-betaxylanases, or other enzymes improving or promoting digestion.

[0055] As peptides possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example avocado peptides, lupin peptides, quinoa peptides, maca peptides, fermented or non-fermented soybean peptides, rice peptides, peptides present in Acacia macrostachya seed extract, peptides present in passionflower seed extracts.

[0056] As amino acids possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, hydroxy-proline, pyrrolysine, selmeno-cysteine, serine, threonine, tryptophan, tyrosine, valine, sarcosine, ornithine.

[0057] As sugars possibly present in said edible pharmaceutical composition (Cp) as defined above, there are for example water-soluble polysaccharides, sugars of lower molecular weight, such as oligosaccharides, mono- or disaccharides, such as for example glucose, lactose, dextrose.

[0058] As flavor enhancers possibly present in the edible pharmaceutical composition (Cp) as defined above, there are for example glutamates, such as glutamic acid, monosodium glutamate, monopotassium glutamate, calcium diglutamate, ammonium glutamate, magnesium diglutamate; guanylates, such as for example guanylic acid (guanosine monophosphate), disodium guanylate, dipotassium guanylate, calcium guanylate, inosinates, such as for example inosinic acid, disodium inosinate, dipotassium inosinate, calcium inosinate, or intense sweeteners such as Stevia extracts, Rebiaudosides.

[0059] Said edible pharmaceutical composition (Cp) may be in solid or liquid form.

[0060] According to a particular aspect of the invention, said edible pharmaceutical composition (Cp) is in the form of a solid, and more particularly the form of a tablet, a capsule, a soft capsule, a powder, a dragee, a confectionery gum or a granule.

[0061] When the edible pharmaceutical composition (Cp) as defined above is in the form of a tablet, it preferably comprises from 50 mg to 150 mg of said composition (C) as defined above, for a 500 mg tablet; when it is in the form of a soft capsule, it preferably comprises from 120 mg to 360 mg of said composition (C) for a 1200 mg soft capsule; when it is in the form of a gelcap, it preferably comprises from 10 mg to 30 mg of composition (C) for a 100 mg gelcap. mg; when it is in the form of a powder, it preferably comprises from 200 mg to 600 mg of composition (C) for a 2000 mg powder.

[0062] When the edible pharmaceutical composition (Cp) is in the form of a powder, it is obtained by introducing its various constituents into a mixer equipped with at least one mechanical stirring system, such as for example flat or propeller-type stirring blades, and the mixer is optionally a turning mixer, and the mixer is optionally equipped with a lump-forming system. This mixing operation is generally carried out at room temperature, in particular between 15°C and 30°C.

[0063] When the edible pharmaceutical composition (Cp) is in the form of a confectionery gum, it preferably comprises from 150 mg to 450 mg of composition (C) for a 1.5 g confectionery gum.

[0064] When the edible pharmaceutical composition (Cp) is in the form of a liquid, it preferably comprises from 100 mg to 300 mg of composition (C) per 1 cm3 ampoule.

[0065] The present invention also relates to said edible pharmaceutical composition (Cp) as defined above, for its use in a therapeutic treatment method intended to promote hair growth, more particularly in people suffering from alopecia or telogen effluvium. The invention also relates to a non-therapeutic method for promoting hair growth, comprising the oral administration of an effective amount of the composition (C) as defined above.

[0066] For the purposes of the present invention, "hair growth" or "hair growth" means the increase in hair length and / or hair regrowth characterized by an increase in the total density of the hair, the density and the proportion of hair in the anagen phase.

[0067] For the purposes of the present invention, the term "effective quantity" means a sufficient quantity which allows the consumer of average attention to visually observe the reality of the aesthetic aspect invoked with regard to the growth of his or her own hair, in particular the increase in the length of the hair and / or the regrowth of the hair.

[0068] The experimental study set out in the remainder of this description shows that an amount of between 1 mg and 250 mg, more particularly between 10 mg and 150 mg, even more particularly between 15 mg and 100 mg, and even more particularly between 30 mg and 70 mg of said composition, ingested per day, can be considered as an effective amount.

[0069] The present invention also relates to a food supplement (Ca) comprising for 100% by mass: - More than 0% by mass to 30% by mass of said composition (C) as defined above and - from 70% by mass to less than 100% by mass of at least one nutritionally acceptable technological additive.

[0070] Preferably, said food supplement (Ca) comprises for 100% by mass: - More than 0% by mass and less than 10% by mass of said composition (C) as defined above and - More than 90% by mass and less than 100% by mass of at least one nutritionally acceptable technological additive.

[0071] A food supplement is understood to mean an edible composition whose purpose is to supplement the normal diet and which constitutes a concentrated source of nutrients or other substances having a nutritional or physiological effect alone or in combination. The food supplement makes it possible to avoid certain deficiencies or to meet specific needs in an individual's diet, in particular during physical exertion. This definition of "food supplement" is given in Article 2 of Decree No. 2006-352 of March 26, 2006 of the French Republic relating to food supplements and in Directive 2002 / 46 / EC of the European Parliament and of the Council of June 10, 2002.

[0072] By "nutritionally acceptable technological additive" is meant a technological additive as defined above, the use of which meets the requirements of the regulations relating to food supplements in force in a country in question.

[0073] According to a particular aspect of the invention, said nutritionally acceptable technological additive is chosen from a diluting agent, a flow agent, a binding agent or a disintegrating agent.

[0074] As diluting agent, there are for example lactose, sucrose, saccharose, glucose, maltodextrin, mannitol, sorbitol, xylitol, isomalt, calcium hydrogen phosphate, microcrystalline cellulose, starches such as corn, wheat or potato starches, dicalcium phosphate, sodium, calcium or magnesium carbonates, monoglycerides and / or diglycerides of fatty acids containing from 8 to 24 carbon atoms.

[0075] Examples of flow agents include magnesium stearate, talc, sodium stearyl fumarate, hydrogenated vegetable oils, anhydrous colloidal silica, sodium benzoate or silicon dioxide.

[0076] As binding agents, there are for example starches in the form of starch, pregelatinized starches, hydroxypropylmethyl cellulose (HPMC), methylcellulose, sucrose syrups or acacia gum.

[0077] As disintegrating agent, there are for example starches, sodium starch glycolate, alginic acid, sodium alginate, croscarmellose sodium, crospovidone, or polyvinylpyrrolidone.

[0078] According to a particular aspect of the invention, said food supplement (Ca) as defined above, further comprises at least one active ingredient chosen from bioactive lipids, water-soluble or water-dispersible trace element salts, water-soluble or fat-soluble vitamins, prebiotics, probiotics, proteins and / or milk protein concentrates, plant or animal enzymes, amino acids, peptides, sugars, flavor enhancers and flavoring agents.

[0079] As bioactive lipids possibly present in said food supplement (Ca) as defined above, there are for example phytosterols, such as those extracted from vegetable oils, and more particularly extracts of sea buckthorn oil, corn oil, or soybean oil; phytosterol complexes isolated from vegetable oils, such as cholestatin composed of campesterol, stigmasterol and bras-sicasterol; phytostanols; carotenoids, which belong to the family of terpenoids extracted from algae, green plants, fungi, bacteria; polyunsaturated fatty acids of the omega-3 group, such as alpha-linoleic acid, eicosapentaenoic acid, docosahexaenoic acid; polyunsaturated fatty acids of the omega-6 group, such as linoleic acid, g-linoleic acid, eicosadienoic acid, dihomo-y-linoleic acid, arachidonic acid, docosadienoic acid, docosatetraenoic acid, docosapentaenoic acid.

[0080] As salts of water-soluble or water-dispersible trace elements possibly present in said food supplement (Ca) as defined above, there are for example ferrous carbonate, ferrous chloride tetrahydrate, ferric chloride hexahydrate, ferrous citrate hexahydrate, ferrous fumarate, ferrous lactate tetrahydrate, ferrous sulfate monohydrate, ferrous sulfate heptahydrate, ferrous chelate of amino acids hydrates, iron chelate of glycine; calcium iodate hexahydrate, anhydrous calcium iodate; sodium iodide, potassium iodide; cobalt acetate tetrahydrate, basic cobalt carbonate monohydrate, cobalt carbonate hexahydrate, cobalt sulfate heptahydrate, cobalt sulfate monohydrate, cobalt nitrate hexahydrate;cupric acetate monohydrate, basic copper carbonate monohydrate, cupric chloride dihydrate, copper methionate, cupric sulfate pentahydrate, cuprous chelate of amino acids hydrates, cuprous chelate of glycine hydrate, copper chelate of hydroxy analogue of methionine; manganous carbonate, manganous chloride tetrahydrate, manganese acid phosphate trihydrate, manganous sulfate tetrahydrate, manganous sulfate monohydrate, manganese chelate of amino acids hydrate, manganese chelate of glycine hydrate, manganese chelate of hydroxy analogue of methionine; ammonium molybdate, molybdate of; sodium, sodium selenite, sodium selenate; the organic form of selenium produced by Saccharomyces cerevisiae, selenomethionine (inactivated selenium yeast), and seleno methionine produced by Saccharomyces cerevisiae (inactivated selenium yeast).

[0081] As water-soluble or fat-soluble vitamins possibly present in said food supplement (Ca) as defined above, there is for example vitamin A, more particularly in its form of retinol, retinyl acetate, retinyl palmitate or beta-carotene; vitamin D2, more particularly in its form of der-gocalciferol, or 25-hydroxy calciferol; vitamin D3, more particularly in its form of cholecalciferol; vitamin K, more particularly in its form of phylloquinone (phytomenadione) or Menaquinone; vitamin B1, more particularly in its form of thiamine hydrochloride, thiamine mononitrate, thiamine chloride monophosphate, or thiamine chloride pyrophosphate, vitamin B2, more particularly in its form of riboflavin, riboflavin 5'-sodium phosphate, vitamin B6, more particularly in its form of pyridoxine hydrochloride, pyridoxine 5'-phosphate,or pyridoxal 5'-phosphate, vitamin B12, more particularly in its form of cyanocobalamin, hydroxocobalamin, 5'-deoxyadenosylcobalamin, or methylcobalamin, vitamin C, more particularly in its form of L-ascorbic acid, sodium L-ascorbate, calcium L-ascorbate, potassium L-ascorbate, calcium salts of palmityl-6-L-ascorbic acid, sodium ascorbyl monophosphate, pantothenic acid, more particularly in its form of calcium D-pantothenate, sodium D-pantothenate, Dexpanthenol, or Pantethine, vitamin PP, more particularly in its form of nicotinic acid, niacin, nicotinamide, or inositol hexanicotinate (hexaniacinate inositol), vitamin B9, more particularly in its folic acid form, folates, more particularly in their pteroylmonoglutamic acid form, calcium L-methylfolate, (6S)-5-methyltetrahydrofolic acid in the form of glucosamine salt,vitamin H2, B7 or BW, more particularly in its biotin form, choline, more particularly in its choline chloride form, choline dihydrogen citrate form, choline bitartrate form, inositol, carnitine, more particularly in its L-carnitine form, L-carnitine-L-tartrate form, taurine.

[0082] As prebiotics possibly present in said food supplement (Ca) as defined above, there are for example inulin, trans-galacto-oligosaccharides, fructans and manno-oligosaccharides.

[0083] As probiotics possibly present in said food supplement (Ca) as defined above, there are different strains of Saccharomyces cerevisiae, Bacillus cereus var toyoi, Bacillus subtilis alone or in combination with the Bacillus licheniformis, or strains of Enteroccocus faecium. These strains of microorganisms are generally associated with a solid support, for example calcium carbonate, dextrose or sorbitol.

[0084] As proteins and / or protein concentrates possibly present in said food supplement (Ca) as defined above, there are for example milk proteins derived from milk, such as colostrum in the form of freeze-dried or atomized powder or whey in the form of powder, purified fractions or enriched with IgG, lactoferrin, lactoperoxidase.

[0085] As plant or animal enzymes possibly present in said food supplement (Ca) as defined above, there are for example promutase, superoxide dismutase (SOD), 3-phytase, 6-phytase, endo-1,4-betaglucanases, endo-1,4-betaxylanases, or other enzymes improving or promoting digestion.

[0086] As peptides possibly present in said food supplement (Ca) as defined above, there are for example avocado peptides, lupin peptides, quinoa peptides, maca peptides, fermented or non-fermented soybean peptides, rice peptides, peptides present in Acacia macrostachya seed extract, peptides present in passionflower seed extracts.

[0087] As amino acids possibly present in said food supplement (Ca) as defined above, there are for example alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, hydroxy-proline, pyrrolysine, selmeno-cysteine, serine, threonine, tryptophan, tyrosine, valine, sarcosine, omithine.

[0088] As sugars possibly present in said food supplement (Ca) as defined above, there are for example water-soluble polysaccharides, sugars of lower molecular weight, such as oligosaccharides, mono- or disaccharides, such as for example glucose, lactose, dextrose.

[0089] As flavor enhancers possibly present in said food supplement (Ca) as defined above, there are for example glutamates, such as glutamic acid, monosodium glutamate, monopotassium glutamate, calcium di-glutamate, ammonium glutamate, magnesium diglutamate; guanylates, such as for example guanylic acid (guanosine monophosphate), disodium guanylate, dipotassium guanylate, calcium guanylate, inosinates, such as for example inosinic acid, disodium inosinate, dipotassium inosinate, calcium inosinate, or intense sweeteners such as Stevia extracts, Rebiaudosides.

[0090] Said food supplement (Ca) may be in solid or liquid form.

[0091] Said food supplement (Ca) may be in any form of food product known to those skilled in the art, such as a drink, and more particularly an aqueous drink, a solution, a fruit juice, a flavored drink, an energy drink, an alcoholic drink, a coffee-based drink, a chocolate-based drink, a tea-based drink, a dairy product, and more particularly milk, yogurt, a dairy dessert, drinking yogurt, cheese, ice cream, a chocolate bar, a cereal product, and more particularly a cereal bar, a biscuit, breakfast cereals, flours, bakery products, a specialized nutrition product, more particularly an infant nutrition product, a nutrition product to prepare for physical exertion, a clinical nutrition product, a meal replacement, confectionery, more particularly chewing gum, candies, caramels,sugared almonds, berlingots, marshmallows, lokoums, nougats, fruit jellies, liquorice.

[0092] The food supplement (Ca) according to the invention may also be presented in any galenic form known to those skilled in the art, such as for example in the form of a tablet, a capsule, a soft capsule, a syrup, a powder, such as for example an immediate-release powder, a delayed-release powder or a powder for reconstituted drinks, a liquid, a stick, a gel.

[0093] According to a particular aspect of the invention, said food supplement (Ca) as defined above, is in the form of a solid, and more particularly the form of a tablet, a capsule, a soft capsule, a powder, a dragee, a confectionery gum or a granule.

[0094] When said food supplement (Ca) as defined above is in the form of a tablet, it preferably comprises less than 50 mg of said composition (C) as defined above, for a 500 mg tablet; when it is in the form of a soft capsule, it preferably comprises less than 120 mg of said composition (C) for a 1200 mg soft capsule; when it is in the form of a capsule, it preferably comprises less than 10 mg of said composition (C) as defined above for a 100 mg capsule; when it is in the form of a powder, it preferably comprises less than 200 mg of said composition (C) as defined above for a 2000 mg powder.

[0095] When said food supplement (Ca) is in the form of a powder, it is obtained by introducing its various constituents into a mixer equipped with at least one mechanical stirring system, such as for example flat or propeller-type stirring blades, and the mixer is optionally a turning mixer, and the mixer is optionally equipped with a lump-forming system. This mixing operation is generally carried out at room temperature. ambient, especially between 15°C and 30°C.

[0096] When said food supplement (Ca) is in the form of a confectionery gum, it preferably comprises less than 150 mg of said composition (C) as defined above for a 1.5 g confectionery gum.

[0097] When the food supplement (Ca) is in the form of a liquid, it preferably comprises less than 100 mg of said composition (C) as defined above for a 1 cm3 ampoule.

[0098] The present invention also relates to the non-therapeutic use of said food supplement (Ca) as defined above, to promote hair growth.

[0099] According to a particular aspect of the invention, said food supplement (Ca) as defined above is administered orally at a rate of at least 15 mg, in particular at least 30 mg, of said composition (C) per day for at least 4 weeks, in particular for at least 8 weeks, even more particularly for 12 weeks.

[0100] The following examples illustrate the invention, without however limiting it. Comparative formulations

[0101] A commercial wheat gluten extract is used in the form of a powdery composition (C) which comprises, for 100% of its mass: 52.5% by mass of sphingolipids, 41.5% by mass of DigalactosylDiacylGlycerol and 6% by mass of phospholipids.

[0102] Two formulations were prepared, respectively a Ca food supplement (comprising composition (C)) and a C'a food supplement (not comprising composition (C)), which comprise the ingredients as indicated in Table 1:

[0103] [Tableauxl] Ingredients Quantity per capsule Food supplement Ca Food supplement C'a Composition (C) 15 mg - Maltodextrin 230 mg 245 mg Dicalcium phosphate 100 mg 100 mg Mg carbonate 50 mg 50 mg Silica 30 mg 30 mg Mg stearate 10 mg 10 mg Total net weight 435 mg 435 mg Total weight (including capsule weight) 549 mg 549 mg Operating mode

[0104] The technical effect of composition (C) was demonstrated in a pilot, randomized, double-blind, parallel-group clinical study. It tested the effect of daily consumption of 30 mg of (C) versus Placebo over a period of 84 days (12 weeks).

[0105] Women of Caucasian ethnicity aged between 18 and 65 years, presenting telogen effluvium (proportion of hair in telogen phase > 15%) and complaining of fine and brittle hair, as well as a sebum level greater than or equal to 140 pg / cm2, were included in the study. They consumed for 84 days (from D0 to D84) either 2 capsules per day of the food supplement Ca or 2 capsules per day of the food supplement C'a. The measurements were carried out on day 0 (D0) and 56 (D56) and 84 days (D84). Al- Hair length: Principle of the evaluation method

[0106] Hair growth was assessed by measuring the length of 5 hairs after 84 days of supplementation, following their shaving on D0.

[0107] Improved hair growth was also evidenced by study subjects through the use of a self-assessment form. Results

[0108] The results obtained are presented in Table 2.

[0109] [Tables2] Dietary supplement C'a (number of subjects = 32) Dietary supplement Ca (number of subjects = 33) Mean ± SEM Mean ± SEM (p vs placebo) D84 3.2 ±0.1 3.6 ±0.1 (p=0.0001)

[0110] ETM: standard error of the measurement Observations - Comments

[0111] By measuring hair growth at D84 after shaving at D0, a significant increase in hair length was observed between the Ca food supplement group (containing composition (C)) and the C'a food supplement group (3.6 ±0.1 cm vs 3.2 ±0.1 cm; p<0.001).

[0112] Furthermore, after analyzing the responses from the qualitative form, a proportion of 91% of the subjects in the Ca food supplement group reported that their “hair grew faster,” compared to 72% of the subjects in the C'a food supplement group. A.2- Hair regrowth: Principle of the evaluation method

[0113] Hair regrowth was assessed by performing a phototrichogram, allowing the density and proportion of hair in the anagen and telogen phases to be quantified. As a reminder, the phototrichogram is performed on a fixed area of ​​the scalp with a diameter of 1.8 cm (frontotemporal region or vertex). The hair is shaved there, before coloring the area and taking a first macrophotograph allowing the total hair to be counted; a second macrophotograph taken 48 hours later then allows the anagen hair that has grown to be differentiated from telogen hair that has not grown.

[0114] Total hair density is assessed by the total number of hairs per cm2.

[0115] Anagen hair density is assessed by the number of hairs in the anagen phase (having grown during the 48 hours between the 2 macrophotographs) per cm2 and proportion (%) in relation to the total hair density.

[0116] Hair regrowth was also analyzed through a clinical assessment performed by a dermatologist as well as using a self-assessment form completed by the study subjects. A.2.1- Hair density in the anagen phase: Results

[0117] The results obtained are presented in Table 3.

[0118] [Tables3] Dietary supplement C'a (number of subjects = 32) Dietary supplement Ca (number of subjects = 33) Mean ± SEM (p vs D0) % vs D0 Mean ± SEM (p vs D0) % vs D0 (p vs placebo) D0 162.6 ± 4.9 - 165.5 ±3.8 - D56 162.8 ±6.1 -0.13% 173.0 ±4.2 (p=0.0005) ±4.6% (p=0.043) D84 170.8 ± 4.9 (p=0.004) ±5.6% 184.6 ±4.1 (p=0.0001) ±11.9% (p=0.004)

[0119] ETM: standard error of the measurement Observations - Comments

[0120] A significant increase in hair density in the anagen phase was observed in the Ca food supplement group after 56 days of consumption: from 165.5 ± 3.8 hairs / cm2 at D0 to 173.0 ± 4.2 hairs / cm2 at D56 (p=0.0005) and 184.6 ±4.1 hairs / cm2 at D84 (p=0.0001), whereas a significant increase was observed in the C'a food supplement group only after 84 days of consumption: from 162.6 ± 4.9 hairs / cm2 at D0 to 162.8 ±6.1 hairs / cm2 at D56 and 170.8 ± 4.9 hairs / cm2 at D84 (p=0.004).

[0121] In addition, there is a significant difference between the Ca food supplement group and the C'a food supplement group at D56 (±4.6% vs -0.13%; p=0.043) as well as at D84 (±11.9% vs ±5.6%; p=0.004).

[0122] A.2.2- The proportion of hair in the anagen phase: Results

[0123] The results obtained are presented in Table 4.

[0124] [Tables4] Dietary supplement C'a (number of subjects = 32) Dietary supplement Ca (number of subjects = 33) Mean + SEM (p vs D0) % vs D0 Mean + SEM (p vs D0) % vs D0 (p vs placebo) D0 81.2 + 0.5 - 80.9 + 0.6 - D56 82.3 + 0.8 +1.3% 84.4 + 0.6 (p=0.0001) +4.3% (p=0.003) D84 83.2 + 0.6 (p=0.002) +2.5% 86.0 + 0.6 (p=0.0001) +6.5% (p=0.0001)

[0125] ETM: standard error of measurement Observations - Comments

[0126] A significant increase in the proportion of hair in the anagen phase was observed in the Ca food supplement group after 56 days of consumption: from 80.9 + 0.6% at D0 to 84.4 + 0.6% at D56 (p=0.0001) and 86.0 + 0.6% at D84 (p=0.0001), whereas a significant increase was observed in the C'a food supplement group only after 84 days of consumption: from 81.2 + 0.5% at D0 to 82.3 + 0.8% at D56 and 83.2 + 0.6% at D84 (p=0.002).

[0127] In addition, there is a significant difference between the Ca food supplement group and the C'a food supplement group at D56 (+4.3% vs +1.3%; p=0.003) and D84 (+6.5% vs +2.5%; p=0.0001). A.2.3- Total hair density: Results

[0128] The results obtained are presented in Table 5.

[0129] [Tables5] Dietary supplement C'a (number of subjects = 32) Dietary supplement Ca (number of subjects = 33) Mean + SEM (p vs D0) % vs D0 Mean + SEM (p vs D0) % vs D0 (p vs placebo) D0 200.5 + 6.3 - 205.1 + 5.1 - D56 197.7 + 7.0 -1.5% 205.3 + 5.1 +0.2% D84 205.4 + 6.0 +2.9% 214.9 + 5.0 (p=0.0001) +5.1%

[0130] ETM: standard error of the measurement Observations - Comments

[0131] A significant increase in total hair density was observed in the Ca food supplement group after 84 days of consumption: from 205.1 ± 5.1 hairs / cm2 at D0 to 214.9 ± 5.0 hairs / cm2 at D84 (p = 0.0001), whereas there was no significant change in the C'a food supplement group: from 200.5 ± 6.3 hairs / cm2 at D0 to 205.4 ± 6.0 hairs / cm2 at D84.

[0132] An increase in total hair density was also noted by clinical assessment (performed by a dermatologist) in 61% of subjects in the Ca supplement group at D56 (vs. 47% of subjects in the C'a supplement group), and in 64% of subjects in the Ca supplement group at D84 (vs. 53% of subjects in the C'a supplement group). This increase was also evidenced by the study subjects, with 85% of subjects in the Ca supplement group reporting that their “scalp was more covered,” compared to 75% of subjects in the C'a supplement group. A.3 Conclusions

[0133] Through the clinical study, composition (C) has demonstrated its activity in promoting hair growth, thanks to its effect on increasing hair length, and its effect on anagen phase density and total density. Examples of illustrative formulations

[0134] [Table 6] Formula for capsules from the clinical study Component Quantity per capsule Composition (C) 15 mg Maltodextrin 230 mg Dicalcium phosphate 100 mg Mg carbonate 50 mg Silica 30 mg Mg stearate 10 mg

[0135] [Table 7] Formula for capsules Component Quantity per capsule Composition (C) 30 mg Maltodextrin 220 mg Beetroot juice 70 mg Mg stearate 15 mg

[0136] [Table 8] Formula for soft capsules Component Quantity per capsule Composition (C) 70 mg Borage oil 400 mg Glyceryl mono stearate 24.1 mg Vitamin C 14.6 mg Lecithin 14 mg Vitamin B 3 2.9 mg Vitamin E 2.7 mg Selenium 2 mg Copper 0.4 mg Vitamin B2 0.2 mg Biotin 0.007 mg

[0137] Bibliography

[0138] (1) Lin et al. Morphogenesis, Growth Cycle and Molecular Regulation. Frontiers in Cell and Developmental Biology 2022, 10:899095.

[0139] (2) Patent application FR3069160A1: Cosmetic or pharmaceutical composition promoting hair growth comprising a lyophilisate of dedifferentiated sea fennel cells.

[0140] (3) Nikfar & Jaberidoost. Hair In Encyclopedia of Toxicology (Third Edition), Academy Press, 2014, 813-815.

[0141] (4) Patent application EP2821052A1: Association of miliacin and lipids polar, in particular sphingolipids and / or phospholipids, for the care of hair and scalp.

[0142] (5) Yin et al. Telogen Effluvium - a review of the science and current obstacles. Journal of Dermatological Science 2021, 101, 156-163.

[0143] (6) Hoffmann. TrichoScan: A Novel Tool For The Analysis of Hair Growth In Vivo. Journal of Investigative Dermatology Symposium Proceedings 2003, 8, 109-115.

Claims

Demands

1. Composition (C) comprising for 100% by mass: - from 20% by mass to 80% by mass of at least one sphin golipid (a1), - from 10% by mass to 50% by mass of digalactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass of at least one phospholipid (a3), for its use in a therapeutic treatment method intended to promote hair growth.

2. Composition (C) according to claim 1, comprising for 100% by mass: - from 20% by mass to 60% by mass of at least one sphin golipid (a1), - from 19% by mass to 50% by mass of digalactosyldiacylglycerol (a2), and - from 1% by mass to 10% by mass of at least one phospholipid (a3).

3. Composition (C) according to any one of claim 1 or 2, characterized in that the sum of the mass contents of said at least one sphingolipid (a1), said digalactosyldiacylglycerol (a2) and said at least one phospholipid (a3) ​​is equal to 100% by mass.

4. Composition (C) according to any one of claims 1 to 3, characterized in that it is a cereal extract, in particular a wheat gluten extract.

5. Edible pharmaceutical composition (Cp) comprising, by weight: - from 10% to 30% by weight of a composition (C) comprising, by weight: - from 20% to 80% by weight, more particularly from 20% to 60% by weight, of at least one sphingolipid (al), - from 10% to 50% by weight, more particularly from 19% to 50% by weight, of diga- lactosyldiacylglycerol (a2), and from 1% by mass to 30% by mass, more particularly from 1% by mass to 10% by mass, of at least one phospholipid (a3), and - from 70% by mass to 90% by mass of at least one pharmaceutically acceptable edible technological additive.

6. Edible pharmaceutical composition (Cp) according to claim 5, further comprising at least one active ingredient selected from bioactive lipids, water-soluble or water-dispersible trace element salts, water-soluble or fat-soluble vitamins, prebiotics, probiotics, milk proteins and / or protein concentrates, plant or animal enzymes, amino acids, peptides, sugars, flavour enhancers and flavouring agents.

7. Edible pharmaceutical composition (Cp) according to any one of claims 5 or 6, for use in a therapeutic treatment method intended to promote hair growth.

8. Composition (C) comprising for 100% by mass: - from 20% by mass to 80% by mass, more particularly from 20% by mass to 60% by mass, of at least one sphingolipid (a1), - from 10% by mass to 50% by mass, more particularly from 19% by mass to 50% by mass, of digalactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass, more particularly from 1% by mass to 10% by mass, of at least one phospholipid (a3), for use in a non-therapeutic method for promoting hair growth, said non-therapeutic method comprising the oral administration of an effective amount of the composition (C).

9. Food supplement (Ca) comprising, by mass: - more than 0% by mass and less than 10% by mass of a composition (C) comprising, by mass: - from 20% by mass to 80% by mass, more particularly from 20% by mass to 60% by mass, of at least one sphingolipid (a1), - from 10% by mass to 50% by mass, more particularly from 19% by mass to 50% by mass, of diga-lactosyldiacylglycerol (a2), and - from 1% by mass to 30% by mass, more particularly from 1% by mass to 10% by mass, of at least one phospholipid (a3), and - more than 90% by mass and less than 100% by mass of at least one nutritionally acceptable technological additive.

10. Food supplement (Ca) according to claim 9, further comprising at least one active ingredient selected from bioactive lipids, water-soluble or water-dispersible trace element salts, water-soluble or fat-soluble vitamins, prebiotics, probiotics, proteins and / or milk protein concentrates, plant or animal enzymes, amino acids, peptides, sugars, ex-flavor enhancers and flavoring agents.

11. Food supplement (Ca) according to any one of claims 9 or 10, characterized in that it is in the form of a solid, and more particularly in the form of a tablet, a capsule, a soft capsule, a powder, a dragee, a confectionery gum or a granule.

12. Dietary supplement (Ca) according to any one of claims 9 to 11, to promote hair growth.

Citation Information

Patent Citations

  • COSMETIC OR PHARMACEUTICAL COMPOSITION PROMOTING HAIR GROWTH COMPRISING A FREEZE-DRIED DEDIFFERENTIATED SEA FRENCH CELL

    FR3069160A1

  • Combination of miliacin and polar lipids, in particular of sphingolipids and / or phospholipids, for care of the hair and scalp

    EP2821052A1

  • A cosmetic composition suitable for strengthening the skin's barrier function, comprising an extract of a non-photosynthetic, non-fruiting filamentous bacterium and an extract of wheat grain.

    FR3126315A1

  • Plant extract based on glycerides, a method for the preparation of this extract and a cosmetic composition containing the same

    US6576266B1

  • Cereal plant extract based on polar lipids

    WO1999065459A1